Norethindrone-Ethinyl Estradiol — Discount Pricing

Other medications in Women's Health

• Oxytocin
• Progesterone Vaginal
• Relugolix
• Terbutaline
• Betamethasone Prenatal
• Carboprost
• Clomiphene Citrate
• Danazol

About Norethindrone-Ethinyl Estradiol

Norethindrone ethinyl estradiol is a widely prescribed medication, primarily used for contraception and managing various gynecological conditions. Understanding its benefits and potential costs is key to consistent treatment. At TheDrugClub, we believe in making essential medications like this more affordable. Discover how our membership can help you save on your prescriptions and simplify your healthcare journey.

What is Norethindrone Ethinyl Estradiol and What Does It Treat?

Norethindrone ethinyl estradiol is a combination oral contraceptive containing two types of female hormones: a progestin (norethindrone) and an estrogen (ethinyl estradiol). While most commonly known as a birth control pill to prevent pregnancy, its applications extend beyond contraception. Healthcare providers also prescribe it to treat a range of gynecological issues, including:

• Endometriosis: It helps manage the pain and symptoms associated with this condition by suppressing the growth of endometrial tissue outside the uterus.
• Heavy or Painful Periods (Menorrhagia and Dysmenorrhea): By regulating the menstrual cycle, it can significantly reduce heavy bleeding and severe cramping.
• Irregular Periods: It helps establish a more predictable menstrual cycle.
• Acne: In some cases, it can improve hormonal acne by balancing hormone levels.

How Does It Work?

This medication works primarily by mimicking the natural hormones in a woman's body to prevent ovulation (the release of an egg from the ovary). The ethinyl estradiol (estrogen) and norethindrone (progestin) components work synergistically to:

1. Stop Ovulation: The consistent dose of hormones prevents the ovaries from releasing an egg each month. 2. Thicken Cervical Mucus: This makes it harder for sperm to travel through the cervix and reach an egg. 3. Thin the Uterine Lining: This makes the uterus less receptive to a fertilized egg, should ovulation or fertilization occur.

Together, these actions provide highly effective contraception and therapeutic benefits for the conditions listed above

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Norethindrone-Ethinyl Estradiol is approved for (FDA label)

WERA™ Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combined oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and the NORPLANT ® System depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. 9 Lactational Amenorrhea Method: LAM is highly effective, temporary method of contraception. 10 Source: Trussell J, Contraceptive efficacy.

Source: Read the full FDA label on DailyMed. Label effective date: April 15, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Norethindrone-Ethinyl Estradiol (FDA label)

WARNING: CARDIOVASCULAR RISK ASSOCIATED WITH SMOKING Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, combination oral contraceptives, including WERA TM , should not be used by women who are over 35 years of age and smoke.

Source: FDA prescribing information (DailyMed). Set ID: 638e4f36-1a27-4220-8ec9-3fa9d9b36c11. SPL document ID: 1f26d981-43da-4b0e-bee1-7d195254fb77. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Norethindrone-Ethinyl Estradiol (FDA label)

Post Marketing Experience: Five studies that compared breast cancer risk between ever-users (current or past use) of COCs and never-users of COCs reported no association between ever use of COCs and breast cancer risk, with effect estimates ranging from 0.90 - 1.12 (Figure 2). Three studies compared breast cancer risk between current or recent COC users (<6 months since last use) and never users of COCs (Figure 2). One of these studies reported no association between breast cancer risk and COC use. The other two studies found an increased relative risk of 1.19 - 1.33 with current or recent use.

Source: FDA prescribing information (DailyMed). Set ID: 638e4f36-1a27-4220-8ec9-3fa9d9b36c11. SPL document ID: 1f26d981-43da-4b0e-bee1-7d195254fb77. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Norethindrone-Ethinyl Estradiol (FDA label)

Oral contraceptives should not be used in women who currently have the following conditions: ● Thrombophlebitis or thromboembolic disorders ● A past history of deep vein thrombophlebitis or thromboembolic disorders ● Known thrombophilic conditions ● Cerebral vascular or coronary artery disease (current or history) ● Valvular heart disease with complications ● Persistent blood pressure values of ≥160 mm Hg systolic or ≥100 mg Hg diastolic 96 ● Diabetes with vascular involvement ● Headaches with focal neurological symptoms ● Major surgery with prolonged immobilization ● Current diagnosis of, or history of, breast cancer, which may be hormone sensitive ● Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia ● Undiagnosed abnormal genital bleeding ● Cholestatic jaundice of pregnancy or jaundice with prior pill use ● Acute or chronic hepatocellular disease with abnormal liver function ● Hepatic adenomas or carcinomas ● Known or suspected pregnancy ● Hypersensitivity to any component

Source: FDA prescribing information (DailyMed). Set ID: 638e4f36-1a27-4220-8ec9-3fa9d9b36c11. SPL document ID: 1f26d981-43da-4b0e-bee1-7d195254fb77. Label effective date: April 15, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.